SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Iambic (NASDAQ:IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder
IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical development in approximately two years Data presented at ESMO 2026 demonstrates IAM1363 was
Iambic Therapeutics, Inc. (Iambic) (NASDAQ:IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering
